Interleukin 12 and antigen independently induce substance P receptor expression in T cells in murine schistosomiasis mansoni

FASEB Journal

Volumn 15, Issue 6, 2001, Pages 950-957

  Blum, Arthur M ^b   Metwali, Ahmed ^b   Crawford, Cathy ^b   Li, Jie ^b   Qadir, Khurram ^b   Elliott, David E ^b   Weinstock, Joel V ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

IL 12; Schistosome egg antigen; Schistosomiasis; Substance P; Substance P receptor

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; MONOCLONAL ANTIBODY; PARASITE ANTIGEN; SUBSTANCE P; SUBSTANCE P RECEPTOR; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNOREACTIVITY; IMMUNOREGULATION; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; ANTIGENS, HELMINTH; DISEASE MODELS, ANIMAL; GRANULOMA; HELMINTH PROTEINS; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; RECEPTORS, NEUROKININ-1; RNA, MESSENGER; SCHISTOSOMIASIS MANSONI; SPLEEN; T-LYMPHOCYTES;

ANIMALIA; MURINAE; SCHISTOSOMA; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI;

EID: 0035069996     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.00-0379     Document Type: Article

References (27)

1. The effects of tachykinins on inflammatory and immune cells
2. Molecular characterization of the three tachykinin receptors
3. Functional neurokinin 1 receptors for substance P are expressed by human vascular endothelium
4. Human monocytes and macrophages express substance P and neurokinin-1 receptor
5. Molecular evidence that granuloma T lymphocytes in murine schistosomiasis mansoni express an authentic substance P (NK-1) receptor
6. Substance P (neurokinin-1) receptor is a marker of human mucosal but not peripheral mononuclear cells: Molecular quantitation and localization
7. Neurokinin-1 (NK-1) receptor is required in Clostridium difficile-induced enteritis
8. Neurogenic amplification of immune complex inflammation
9. Impaired IL-1beta-induced neutrophil accumulation in tachykinin NK1 receptor knockout mice
10. A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei
11. Increased susceptibility of mice to Salmonella infection following in vivo treatment with the substance P antagonist, spantide II
12. The substance P and somatostatin interferon-gamma immunoregulatory circuit
13. Eosinophils from granulomas in murine schistosomiasis mansoni produce substance P
14. The substance P receptor is necessary for a normal granulomatous response in murine schistosomiasis mansoni
15. Substance P modulates antigen-induced. IFN-gamma production in murine Schistosomiasis mansoni
16. Substance P and somatostatin can modulate the amount of IgG2a secreted in response to schistosome egg antigens in murine schistosomiasis mansoni
17. Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis
18. Methods used to study immunoregulation of schistosome egg granulomas
19. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
20. IL-4 and IFN-γ up-regulate substance P receptor expression in murine peritoneal macrophages
21. Localization and regulation of IFN-γ production within the granulomas of murine schistosomiasis in IL-4 deficient and control mice
22. Substance P diminishes lipopolysaccharide and interferon-gamma-induced TGF-beta 1 production by cultured murine macrophages
23. Expression of NK-1 receptor mRNA in murine T lymphocytes
24. Substance P (NK1)- and neurokinin A (NK2)-receptor gene expression in inflammatory airway diseases
25. Substance P receptor antagonist inhibits murine IgM expression in developing schistosome granulomas by blocking the terminal differentiation of intragranuloma B cells
26. Regulation of interferon-gamma production by IL-12 and IL-18
27. Interleukin-12: Basic principles and clinical applications